Changeflow GovPing Pharma & Drug Safety Oligopeptide Inhibits Angiogenesis and Vascular...
Routine Notice Added Final

Oligopeptide Inhibits Angiogenesis and Vascular Function

Favicon for changeflow.com ChangeBridge: Patent Apps - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO published patent application US20260091078A1 covering an oligopeptide composition of 3-7 amino acids that inhibits angiogenesis and vascular function. The oligopeptide comprises defined sequence patterns with basic, small, polar, and hydrophobic amino acid residues. The application claims priority from July 7, 2020.

What changed

The USPTO published a patent application for an oligopeptide therapeutic composition with anti-angiogenic and vascular function-inhibiting properties. The claims cover oligopeptides of 3-7 amino acids with specific sequence motifs: X2-X3-X4 (3-mer), X1-X2-X3-X4 (4-mer), and X1-X2-X3-X4-X5-X6-X7 (7-mer), where positions are defined by amino acid properties (basic, small, polar, hydrophobic). The application is classified under A61K 38/08, A61P 9/00, A61P 27/02, and C07K 16/18.

This patent publication is informational for entities in the pharmaceutical and biotechnology sectors. Competitors developing peptide-based therapeutics targeting angiogenesis should conduct freedom-to-operate analyses and review this application during prior art searches. No compliance deadlines or regulatory obligations are imposed by this document.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

OLIGOPEPTIDE THAT INHIBITS ANGIOGENESIS AND VASCULAR FUNCTION

Application US20260091078A1 Kind: A1 Apr 02, 2026

Inventors

Jakob TRIEBEL, Thomas Bertsch, Marid del Carmen Clapp Jiminez L., Juan Pablo Robles Alvarez, Maria Magdalena Zamora Corona, Gonzalo Martinez de la Escalera Lorenzo

Abstract

An oligopeptide that inhibits angiogenesis and vascular function which oligonucleotide has a length of 3 to 7 amino acids and comprises or consists of the sequence X2-X3-X4, wherein X2 is a basic or amide amino acid, X3 is a small amino acid and X4 is a basic amino acid, charged at neutral pH or the sequence X1-X2-X3-X4, wherein X1 is a polar non-charged amino acid and X2, X3 and X4 are identical to X2, X3 and X4 in X2-X3-X4, or the sequence X1-X2-X3-X4-X5-X6-X7, wherein X1, X2, X3 and X4 are identical to X1, X2, X3 and X4 in X1-X2-X3-X4, X5 is a small amino acid, X6 is a hydrophobic amino acid and X7 is a hydrophobic amino acid.

CPC Classifications

A61K 38/08 A61P 9/00 A61P 27/02 C07K 16/18

Filing Date

2020-07-07

Application No.

17778396

View original document →

Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260091078A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing 6211 Healthcare Providers
Activity scope
Patent Filing Drug Development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.